Janssen initiated a patent infringement action pursuant to ss 6(1) of the PMNOC Regulations, relating to Canadian Patent No. 2,655,335, and Janssenâs INVEGA SUSTENNAÂź (paliperidone palmitate). Teva filed an ANDS with Health Canada seeking approval to sell its own paliperidone palmitate product in Canada. On Jan. 9, 2018, Teva served Janssen with a Notice of Allegation pursuant to the Regulations, and Janssen commenced this action.